The filing comes as Hanmi's Epe, approved October 7, is expected to launch near 100,000 won a month, about half what Wegovy and Mounjaro cost.
Recap by typeshit. Full story at 아시아경제.
A TV segment airing on WSIL and KFVS looks at the weight loss drug trend and what coverage people might be able to get through their insurance today.
Monthly units climbed from 114,000 in February to 434,000 in September, and sales value rose from ₹48 cr to ₹113 cr as doctors report wider access.
Lilly is lowering what it charges for one of its weight loss drugs. The headline doesn't say which drug or by how much.
Access to Ozempic, Wegovy and Mounjaro in Australia often comes down to who can pay, raising the question of public subsidies.
A new 'In Discussion With' episode has pharmacist Sehar Shahid weighing in on obesity risk. The preview gives little beyond the topic.
The engineered peptides are said to kill resistant bacteria while sparing human cells. Details on the study and its source are thin.
Loading…